You are here

Herzuma Approved for Treatment of Breast Cancer

New Biosimilar Provides Broader Treatment Options for Patients

The FDA has approved another biosimilar for the adjuvant treatment of HER2 overexpressing, node-positive or node-negative breast cancer. In addition, this biosimilar Herzuma (trastuzumab-pkrb, Celltrion, South Korea, and Teva Pharmaceutical, Israel) is approved as part of a first-line treatment for metastatic breast cancer combined with chemotherapy.

Common adverse events associated with the use of trastuzumab-pkrb for treatment of HER2-positive breast cancers include diarrhea, headache, chills, nausea, fever, infection, insomnia, congestive heart failure, cough and rash. Serious adverse effects can include worsening of chemotherapy-induced neutropenia.

Like its reference product trastuzumab (Herceptin, Genentech), trastuzumab-pkrb carries a boxed warning about elevated risks for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.

Source: Biospace.com, December 17, 2018

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status